Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05997732
Other study ID # Pro00126600
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 31, 2023
Est. completion date September 1, 2024

Study information

Verified date October 2023
Source University of Alberta
Contact Emily Vanden Berg, MSc
Phone (780)-492-5553
Email ervanden@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this interventional study is to examine differences in resting blood pressure control between healthy males and females. The main questions it aims to answer are: 1. Are there sex differences in the communication between the sympathetic nervous system (also known as the "fight or flight" response) and peripheral blood vessels (which influence systemic blood pressure)? 2. What is the role of specific vascular receptors that respond to sympathetic signals, and is it different between males and females? Participants will complete one study visit of approximately 3 hours where they will: - Have a blood sample taken to measure circulating sex hormone and sympathetic transmitters. - Receive very small doses of medications commonly used to adjust blood pressure through an artery in their arm. The effects of these medications will be short-acting and localized to the forearm. - Have their sympathetic nervous activity directly measured through two very small needles (similar to acupuncture needles) in the side of their leg. - Have their blood pressure and heart rate recorded, and forearm blood flow measured using ultrasound.


Description:

Blood pressure is in part regulated by activity of your sympathetic nervous system (also known as your "fight or flight" response). Sympathetic nerve activity affects the size of your blood vessels, which in turn will affect your blood pressure. This communication between sympathetic impulses and the resulting change in vascular resistance is termed "sympathetic neurovascular transduction". In other words, transduction represents the reactivity of the blood vessels in response to individual sympathetic bursts of activity. Males and females regulate their blood pressure in different ways; for example, females tend to have lower blood pressure and sympathetic nerve activity than males. Females also appear to have less constriction of their blood vessels in response to stress. This may be due to differences in the receptors which are activated by the sympathetic nervous system. These receptors are called α and β-adrenergic receptors and are located on vascular smooth muscle cells. They respond to sympathetic neurotransmitters such as norepinephrine in opposite directions: α-adrenoreceptors cause vasoconstriction (and an increase in vascular resistance), and β-adrenoreceptors cause vasodilation (and a decrease in vascular resistance) in part through the endothelium-dependent nitric oxide pathway. Current evidence suggests that β-adrenergic receptors are more sensitive in females and contribute to paradoxical vasodilation when α-adrenergic receptors are stimulated by norepinephrine from sympathetic bursts. It has also been suggested that estrogen interacts with adrenergic receptors, contributing to this sex difference. This study will contribute to the understanding of sex differences in cardiovascular physiology and may have implications for clinical cardiovascular conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Between ages 18-40 years - No diagnosed medical history of cardiovascular, respiratory, nervous system, or metabolic disease. - Females must be pre-menopausal. - Prior to study visit: abstained from caffeine, alcohol, strenuous exercise, and medication not taken regularly for at least 12 hours. Exclusion Criteria: - Current diagnosis of cardiovascular, respiratory, nervous system, or metabolic disease that may impact blood pressure regulation. This will be assessed on a case-by-case basis by the study physician. - Participants with bleeding or clotting disorders, or those currently taking blood thinners. - Participants currently taking beta-agonist inhalers i.e. Ventolin (at least not in the last 24 hours). - Females who are pregnant, confirmed by a pregnancy test. - Females who have are less than 1 year postpartum or are breastfeeding. - Females who are post-menopausal. - Participants that are classified as obese (body mass index > 30 kg · m2). - Have a history of smoking regularly in the last 6 months (but nicotine substitutes (i.e. patch, gum) are not an exclusion criteria). - Those with a known allergy to sulfites, or other components of the supplied solution of study drugs. - Participants taking medications that are contraindicated with any of the study drugs, such as monoamine oxidase (MAO) inhibitors or tricyclic antidepressants. - Participants who have not adhered to the pre-testing guidelines related to diet, alcohol or exercise will not be excluded, but will be rescheduled for a different day. This is to reduce experimental variability.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Phenylephrine Hydrochloride
Participants will receive three incremental doses via the brachial artery catheter to assess a1-adrenoreceptor mediated vasoconstriction.
Isoproterenol Hydrochloride
Participants will receive four incremental doses via the brachial artery catheter to assess ß-adrenoreceptor mediated vasodilation.
Norepinephrine Bitartrate
Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
Propranolol Hydrochloride
Propranolol will be continuously infused through the brachial artery catheter to induce ß-adrenergic blockade locally in the forearm.
Phentolamine Mesylate
Phentolamine will be continuously infused through the brachial artery catheter to induce a-adrenergic blockade locally in the forearm.
Phenylephrine Hydrochloride
Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the a-adrenergic blockade.
Isoproterenol Hydrochloride
Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the ß-adrenergic blockade.
Propranolol Hydrochloride
Propranolol will be continuously co-infused with phentolamine to maintain the ß-adrenergic blockade.

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Dinenno FA, Eisenach JH, Dietz NM, Joyner MJ. Post-junctional alpha-adrenoceptors and basal limb vascular tone in healthy men. J Physiol. 2002 May 1;540(Pt 3):1103-10. doi: 10.1113/jphysiol.2001.015297. — View Citation

Fairfax ST, Holwerda SW, Credeur DP, Zuidema MY, Medley JH, Dyke PC 2nd, Wray DW, Davis MJ, Fadel PJ. The role of alpha-adrenergic receptors in mediating beat-by-beat sympathetic vascular transduction in the forearm of resting man. J Physiol. 2013 Jul 15;591(14):3637-49. doi: 10.1113/jphysiol.2013.250894. Epub 2013 May 7. — View Citation

Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach JH, Joyner MJ. Sex differences in sympathetic neural-hemodynamic balance: implications for human blood pressure regulation. Hypertension. 2009 Mar;53(3):571-6. doi: 10.1161/HYPERTENSIONAHA.108.126391. Epub 2009 Jan 26. — View Citation

Hissen SL, Taylor CE. Sex differences in vascular transduction of sympathetic nerve activity. Clin Auton Res. 2020 Oct;30(5):381-392. doi: 10.1007/s10286-020-00722-0. Epub 2020 Aug 31. — View Citation

Steinback CD, Fraser GM, Usselman CW, Reyes LM, Julian CG, Stickland MK, Chari RS, Khurana R, Davidge ST, Davenport MH. Blunted sympathetic neurovascular transduction during normotensive pregnancy. J Physiol. 2019 Jul;597(14):3687-3696. doi: 10.1113/JP277714. Epub 2019 Jun 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Forearm blood flow Measured during resting baseline; changes during phenylephrine, isoproterenol, and norepinephrine infusion to determine agonist sensitivity. 10 minutes per condition + 2 minutes per agonist dose = 60 minutes
Primary Forearm vascular resistance Measured during resting baseline; changes during phenylephrine, isoproterenol, and norepinephrine infusion to determine agonist sensitivity. 10 minutes per condition + 2 minutes per agonist dose = 60 minutes
Primary Forearm vascular conductance Measured during resting baseline; changes during phenylephrine, isoproterenol, and norepinephrine infusion to determine agonist sensitivity. 10 minutes per condition + 2 minutes per agonist dose = 60 minutes
Primary Arterial blood pressure Measured during resting baseline; changes during phenylephrine, isoproterenol, and norepinephrine infusion to determine agonist sensitivity. 10 minutes per condition + 2 minutes per agonist dose = 60 minutes
Primary Muscle sympathetic nerve activity Resting baseline 10 minutes per condition = 30 minutes
Primary Circulating sex hormone concentrations Blood samples 2 minutes
Primary Circulating sympathetic neurotransmitter concentrations Blood sample 2 minutes
Secondary Arterial-venous blood gas concentrations Blood sample during each condition 2 minutes per sample = 6 minutes
See also
  Status Clinical Trial Phase
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Active, not recruiting NCT06454084 - Investigation of Endothelium-dependent Vasodilation in Human Gingiva N/A
Recruiting NCT06117007 - Effects of Betalains on Cardiovascular Health and Quality of Life N/A
Completed NCT03659864 - The Role of Eicosanoids in the Cardiovascular Actions of Inhaled Nanoparticles N/A
Completed NCT03459027 - Nitrate Supplementation and Muscle Blood Flow N/A
Recruiting NCT04255160 - Impact of Estradiol on Endothelial Function in Peri-Menopausal Women Phase 4
Recruiting NCT05522075 - Reducing Blood Pressure in Mid-life Adult Binge Drinkers N/A
Completed NCT00184886 - The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans N/A
Completed NCT02095873 - Healthy Aging Through Functional Food Phase 1/Phase 2
Completed NCT02292342 - An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men Phase 0
Completed NCT00901745 - Interaction of Apelin and Angiotensin in the Human Forearm Circulation N/A
Not yet recruiting NCT06290713 - Vasodilator and Exercise Study for DMD (VASO-REx) Phase 2
Completed NCT02265107 - Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft N/A
Recruiting NCT05219799 - Sex Disparities in Hypoxic Vasodilation and Impact of Obesity Early Phase 1
Completed NCT03622060 - Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery Occlusion Phase 3
Not yet recruiting NCT06417177 - Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia Early Phase 1
Completed NCT01618071 - Vascular Effects of Triglyceride-rich Lipoproteins N/A
Completed NCT03190304 - The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure Phase 4
Completed NCT04928183 - The Impact of Carbon Monoxide and Altitude on Vascular Function N/A
Suspended NCT04001647 - Targeting ER Stress in Vascular Dysfunction Early Phase 1